279 related articles for article (PubMed ID: 33251978)
1. Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Liu J; Han Y; Liu X; Wei S
Technol Cancer Res Treat; 2020; 19():1533033820973276. PubMed ID: 33251978
[TBL] [Abstract][Full Text] [Related]
2. Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Chen L; Li Y; Lu J
Technol Cancer Res Treat; 2020; 19():1533033820964222. PubMed ID: 33317398
[TBL] [Abstract][Full Text] [Related]
3. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
4. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients.
Zhang Y; Xu H
J Clin Lab Anal; 2020 Jun; 34(6):e23237. PubMed ID: 32061007
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
7. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
8. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
9. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.
Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X
J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
11. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
12. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
13. Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer.
Wang K; Dong L; Fang Q; Xia H; Hou X
Cancer Biomark; 2017 Sep; 20(3):283-288. PubMed ID: 28946561
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer.
Liu W; Liu J; Zhang Q; Wei L
Cancer Biomark; 2020; 27(1):113-120. PubMed ID: 31771047
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
Li LL; Qu LL; Fu HJ; Zheng XF; Tang CH; Li XY; Chen J; Wang WX; Yang SX; Wang L; Zhao GH; Lv PP; Zhang M; Lei YY; Qin HF; Wang H; Gao HJ; Liu XQ
Oncotarget; 2017 Jul; 8(28):45399-45414. PubMed ID: 28514730
[TBL] [Abstract][Full Text] [Related]
17. Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer.
Xie H; Chen J; Lv X; Zhang L; Wu J; Ge X; Yang Q; Zhang D; Chen J
Technol Cancer Res Treat; 2020; 19():1533033820947490. PubMed ID: 32851926
[TBL] [Abstract][Full Text] [Related]
18. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer.
Zhu W; He J; Chen D; Zhang B; Xu L; Ma H; Liu X; Zhang Y; Le H
PLoS One; 2014; 9(2):e87780. PubMed ID: 24523873
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer.
Ding H; Wen W; Ding Q; Zhao X
Cancer Control; 2020; 27(1):1073274820964783. PubMed ID: 33104396
[TBL] [Abstract][Full Text] [Related]
20. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]